THE PROTEKT STUDY - A PHASE IIA, RANDOMISED, CONTROLLED, OPEN-LABEL TRIAL OF ROSUVASTATIN FOR THE PREVENTION OF AMINOGLYCOSIDE-INDUCED KIDNEY TOXICITY IN CHILDREN WITH CYSTIC FIBROSIS



McWilliam, SJ ORCID: 0000-0002-0509-7425, Antoine, DJ, Rosala-Hallas, A ORCID: 0000-0001-8012-9995, Jones, A, MacLean, C, Prayle, A, Smyth, AR, Flaherty, L, Shaw, VE, Greenhalf, W
et al (show 2 more authors) (2017) THE PROTEKT STUDY - A PHASE IIA, RANDOMISED, CONTROLLED, OPEN-LABEL TRIAL OF ROSUVASTATIN FOR THE PREVENTION OF AMINOGLYCOSIDE-INDUCED KIDNEY TOXICITY IN CHILDREN WITH CYSTIC FIBROSIS. In: 31st Annual North American Cystic Fibrosis Conference, 2017-11-2 - 2017-11-4, Indiana Convention Center, Indianapolis, Indiana.

[img] Text
NACFC Abstract 230517.docx - Author Accepted Manuscript

Download (16kB)
Item Type: Conference or Workshop Item (Unspecified)
Depositing User: Symplectic Admin
Date Deposited: 04 Dec 2017 10:00
Last Modified: 19 Jan 2023 06:52
DOI: 10.1002/ppul.23840
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3010363